ASX ANNOUNCEMENT

ASX: 1AI | 5 November 2026

Annual General Meeting: Chairman's Address to Shareholders

Melbourne, Australia, 5 November 2026: Algorae Pharmaceuticals Limited ('Algorae' or 'the Company') (ASX code: 1AI) is pleased to enclose the address of the Chairman at the Annual General Meeting being held today.

Opening

Good morning, ladies and gentlemen.

On behalf of the Board of Directors, I welcome you to the 2026 Annual General Meeting of Algorae Pharmaceuticals.

A year ago, Algorae had just signed its first commercial partner. Today, alongside our AI drug discovery platform, we have partnerships with many leading international pharmaceutical manufacturers, including Dr. Reddy's, Zydus and Torrent, five product registrations under review with the TGA, and an approved-supplier position with NSW public hospitals. The 2026 financial year was one of building across both sides of the business, and I will take you through what we achieved, where we stand and what comes next.

Commercial Progress: Building AlgoraeRx

Last year I described our agreement with Sakar Healthcare as Algorae's first step toward a branded presence in Australia and New Zealand. This year we took the next five and beyond: a licence and supply agreement with Cadila Pharmaceuticals; a distribution agreement with Dr. Reddy's Laboratories; an exclusive agreement with Zydus Lifesciences; a licence and supply agreement with Torrent Pharmaceuticals; and, last month, a binding agreement with Umedica Laboratories for a first product, together with a non-binding MOU covering eight further molecules.

Together with Sakar, these agreements provide AlgoraeRx with a portfolio of more than twenty products across oncology, cardiovascular, metabolic and specialty medicines, with opportunities to supply both the hospital and retail channels. The willingness of manufacturers of this standing to partner with AlgoraeRx is a strong endorsement of the business Vishal Shah and the commercial team have built.

The second half of the year was about regulatory execution. In April, the TGA accepted our first product registration dossier for evaluation. Today we have seven product registrations under review with the TGA, and the Umedica dossier was lodged last month.

Then in July, following a competitive tender, AlgoraeRx was appointed a supplier to NSW public hospitals under a standing offer arrangement with NSW Health, for an initial three-year term with two one-year extension options. Onboarding and rollout are under way, first supply under purchase orders is expected this quarter, and the award gives us the credentials to compete for further hospital tenders.

To fund inventory without diluting shareholders, in January we secured a $3.0 million working capital facility with ScotPac. With supply agreements, registrations under review and a hospital

supply position in place, we now have a clear pathway to scale, and the September quarter brought our first customer receipts, the first step in converting what we have built into revenue.

AlgoraeOS: From Prediction to Proof

A year ago, I told you AlgoraeOS Version 2 was in final refinement and that our first Peter Mac results were due in the fourth quarter. Both commitments were met.

In November 2025, we launched Version 2, developed with the UNSW AI Institute and supported by CSIRO Data61. Trained on more than five and a half million inhibition records, it outperformed state-of-the-art models in published benchmarks, including two from Google DeepMind.

Independent testing at Peter Mac then showed the platform works in the laboratory. In December, Version 1 correctly identified synergistic combinations across four cancer cell lines and excluded most of those that were not. In July, Version 2 identified a roughly two-and-a-half-fold higher proportion of confirmed synergistic combinations than Version 1.

With the platform validated, we scaled it. A multi-anchor program generated more than nine million predictions, from which we curated 40 high-priority candidates now being screened in our third Peter Mac program, co-funded by a competitive Phenomics Australia grant. Results are expected within six months.

AlgoraeOS is now generating a pipeline of drug-combination candidates at scale. Our strategy is to protect the strongest as they are validated and make them available to partners for licensing and co-development.

Financial Position and Capital Management

This year, our spending was an investment in future revenue: building our commercial capability, funding the research that validated and scaled AlgoraeOS, and investing in inventory and product registrations ahead of first supply.

Our balance sheet is materially stronger. In April, we raised $4.0 million, principally from existing long-term shareholders, a clear vote of confidence from those who know us best. We closed the year with cash and term deposits of $3.94 million, up from $2.32 million a year earlier, and at 30 September held cash of $3.15 million and total available funding of $6.15 million, with the ScotPac facility undrawn. We also expect to receive our R&D tax incentive refund this quarter, further strengthening our position. Every dollar is directed to bringing our products to market and our pipeline to partners, and we will continue to manage capital with discipline as the business scales.

Governance and Team

This year we strengthened both the Board and management with the hospital, commercial and capital markets experience our next phase demands.

In March, David Gulland joined the Board. As General Manager of HPS Pharmacies within EBOS Group, David ran a $500 million national hospital pharmacy operation. In July, Troy Valentine joined as a Non-Executive Director. Troy is Chairman of Nasdaq-listed Incannex Healthcare, which he took from the ASX to a US listing while raising more than $220 million, and brings more than 27 years' experience in capital markets and listed-company governance.

In management, Vishal Shah now leads AlgoraeRx as Managing Director. He is joined by Head of Sales Waleed Elsayed, who brings deep hospital market experience from his previous role as Head of Hospital Sales at Sandoz Australia and New Zealand.

Outlook and Key Milestones to Watch

Last year I spoke of confidence, momentum and strategy. This year I would add a fourth word: execution. The agreements are signed, the platform is validated and the team is in place. Now we convert that into products on shelves, data in hand and revenue in the accounts.

On the commercial side, watch for first supply to NSW public hospitals, TGA decisions on our dossiers, further registration submissions and additional hospital tenders. On the discovery side, watch for results from our third Peter Mac program, the advancement of our best candidates and the patent filings that follow.

Taken together, Algorae has a validated AI discovery engine producing a pipeline at scale, a commercial business with five products under TGA review, and a stronger balance sheet to support the next stage of growth. That combination gives us a strong foundation for growth.

Closing

I thank our research partners at UNSW, CSIRO Data61 and Peter Mac; our manufacturing partners, for their trust in a young Australian company; our small, hard-working team; my fellow directors; and our shareholders, for their continued backing.

The chapter I invited you into last year has been written. In the next, Algorae builds a meaningful revenue base, and I look forward to reporting to you on it.

Thank you.

This announcement has been approved by the Board of Directors.

ENDS.

Corporate and Media Enquiries

Mr David Hainsworth

Executive Chairman

E: inquiries@algoraepharma.com

About Algorae Pharmaceuticals

Algorae Pharmaceuticals Ltd (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies artificial intelligence to identify synergistic drug combinations and inform preclinical experimental design.

In parallel, Algorae operates a commercialisation business, AlgoraeRx, which sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through manufacturing partners and established distribution channels. Algorae collaborates with research institutions and industry partners to translate AI-predicted therapies and expand patient access to high-quality medicines.

For more information visit www.algoraepharma.com or follow @algoraepharma on X or LinkedIn.

Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the TGA's, the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.